Source link : https://www.newshealth.biz/health-news/pd-1-inhibitor-plus-chemotherapy-shows-promising-activity-in-rare-lymphoma/
An investigational PD-1 inhibitor combined with chemotherapy showed impressive activity in treatment-naive patients with advanced extranodal natural killer/T-cell lymphoma (ENKTL), according to results from a small Chinese single-arm phase II trial. At a median follow-up of 21 months, 29 of 34 patients (85%) treated with sintilimab and P-GEMOX (pegaspargase, gemcitabine, and oxaliplatin) achieved a complete […]
Author : News Health
Publish date : 2024-03-28 16:22:57
Copyright for syndicated content belongs to the linked Source.